Table 1.

Demographic and clinical characteristics of patients with giant CAA during the acute disease

	Giant CAA n = 45
Male gender, n (%)	41 (91)
Age at disease onset (years)a	1.0 (0.3–2.8)
Complete disease, n (%)	29 (64)
IVIG treatment, n (%)	44 (98)
Day first IVIG treatment+a	10 (7–18)
Second IVIG treatment, n (%)	19 (42)
Steroid treatment, n (%)	11 (24)
Highest-ever z-scorea	17.1 (14.0–24.1)
Highest-ever diameter (mm)a	6.9 (5.7–8.5)
Follow-up time (years)a	6.9 (2.6–15)

IVIG intravenous immunoglobulins

^aMedian (interquartile range), + Day calculated from first day of fever